Aptorum Group Ltd banner

Aptorum Group Ltd
NASDAQ:APM

Watchlist Manager
Aptorum Group Ltd Logo
Aptorum Group Ltd
NASDAQ:APM
Watchlist
Price: 0.799 USD 1.01% Market Closed
Market Cap: $6.5m

Aptorum Group Ltd
Non-Reccuring Items

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Aptorum Group Ltd
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
Aptorum Group Ltd
NASDAQ:APM
Non-Reccuring Items
-$1.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
Non-Reccuring Items
-$34.1m
CAGR 3-Years
46%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bicycle Therapeutics PLC
NASDAQ:BCYC
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Compass Pathways PLC
NASDAQ:CMPS
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Genus PLC
LSE:GNS
Non-Reccuring Items
-£29.5m
CAGR 3-Years
-59%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
Oxford BioMedica PLC
LSE:OXB
Non-Reccuring Items
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Aptorum Group Ltd
Glance View

Market Cap
6.5m USD
Industry
Biotechnology

Aptorum Group Ltd. is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs. The company is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other. Its projects include Smart-Act series, Acticule series, RPIDD, Nativus series and Claves series. SMART-ACT is a drug delivery platform, focused on orphan diseases. SMART-ACT pipeline includes SACT-1 and SACT-COV19. Its Acticule series includes ALS-4, ALS-1 and ALS-2/3. ALS-4 is an anti-virulent, non-bacterial drug candidate for staphylococcus aureus infections. ALS-1 is an antiviral therapeutic against Influenza A. ALS-3/3 is an anti-virulent, non-bacterial approach therapeutics targeting Gram-positive bacteria. RPIDD is therapeutic against infection disease. Nativus series includes NativusWell (NLS-2), nutraceutical supplement targeting women who are between 45 ad 65 years old and experiencing menopausal, premenopausal, postmenopausal syndrome.

APM Intrinsic Value
1.264 USD
Undervaluation 37%
Intrinsic Value
Price

See Also

What is Aptorum Group Ltd's Non-Reccuring Items?
Non-Reccuring Items
-1.8m USD

Based on the financial report for Dec 31, 2024, Aptorum Group Ltd's Non-Reccuring Items amounts to -1.8m USD.

What is Aptorum Group Ltd's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 1Y
-145%

Over the last year, the Non-Reccuring Items growth was -145%.

Back to Top